Somagenetix Logo.png
Somagenetix AG secures CHF 10 million in Series A financing to advance lentiviral gene therapy for Chronic Granulomatous Disease (CGD)
08. Oktober 2024 04:00 ET | Somagenetix AG
ZURICH, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Somagenetix AG, a pioneering biotech company dedicated to revolutionizing gene therapy for phagocyte disorders, announced today the initial closing of its...